Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX). GLM-IV is…Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…Abstract Number: 1543 • 2016 ACR/ARHP Annual Meeting
Obese Patients with RA Have a More Seropositive and a More Active Disease with Less Deformities
Background/Purpose: An association between obesity and RA activity has been proposed in the literature. Kuwait has the highest obesity rate in The Middle East and…Abstract Number: 2230 • 2016 ACR/ARHP Annual Meeting
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Background/Purpose: The goal of this study was to validate a claims-based statistical model to predict disease activity measured by the 28-joint count Disease Activity Score…Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…Abstract Number: 2597 • 2016 ACR/ARHP Annual Meeting
Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry
Background/Purpose: Despite new effective therapies for Rheumatoid Arthritis (RA), glucocorticoids (GC) are widely prescribed. It is possible that dose and duration of GC therapy may…Abstract Number: 2605 • 2016 ACR/ARHP Annual Meeting
Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Background/Purpose: Recently issued guidelines suggest that rheumatoid arthritis (RA) patients with previously treated solid malignancy may be treated as patients without such history (1). The…Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…Abstract Number: 600 • 2016 ACR/ARHP Annual Meeting
Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry
Background/Purpose: Dose escalation is a common strategy for patients (pts) on infliximab (IFX). This study examined the trend in disease activity across dose escalations to…